Euroscreen Announces Chemerin and F2L Products and Services License with Phoenix Pharmaceuticals Inc.

Share Article

Euroscreen s.a. has completed a non-exclusive license agreement with Phoenix Pharmaceuticals Inc. for access to the Euroscreen's Chemerin and F2L patent rights. Financial details of this Agreement were not disclosed.

Euroscreen s.a. has completed a non-exclusive license agreement with Phoenix Pharmaceuticals Inc. for access to the Euroscreen's Chemerin and F2L patent rights. Financial details of this Agreement were not disclosed.

The license agreement covers the commercial activities conducted by Phoenix Pharmaceuticals related to Chemerin and F2L Products protected the Euroscreen's patent rights. Under the terms of this license agreement Phoenix Pharmaceuticals will be able to develop and provide the research community with high quality Chemerin and F2L products and services for research purposes only. Phoenix Pharmaceuticals customers would need to apply to Euroscreen for any potential license opportunities regarding further therapeutic and/or diagnostic applications based on Chemerin and F2L products.

Commenting on the announcement, Dr. Vincent Lannoy, Business Development and Licensing Manager at Euroscreen, said: "We are very pleased that Phoenix Pharmaceuticals will provide the Chemerin and F2L products and services under the terms of this License Agreement. Such top quality products will be used both by academic and corporate research teams to increase the knowledge of promising GPCR targets, namely the Chemerin Receptor and FPRL2 Receptor".

For further Information, please contact:
LicensingBD @ euroscreen.com

EUROSCREEN S.A.
Tel: +32 71 348 500, Fax: +32 71 348 519

Jean Combalbert, Ph. D.
Chief Executive Officer

Vincentl Lannoy, Ph. D.
Manager of Business Development & Licensing

About EUROSCREEN S.A.
EUROSCREEN is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium, focused on the discovery and development of small molecule drugs for unmet medical needs. Founded in 1994, as a spin-off of the "Université Libre de Bruxelles", initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, EUROSCREEN is now developing a pipeline of preclinical candidates targeting proprietary GPCR, such as CCR5, as well as several preclinical-stage collaborations with partners, using its worldwide recognized expertise on this critical class of drug targets.

EUROSCREEN pursues a dual business model strategy of combining its internal programs on high value targets (EUROSCREEN DRUG DISCOVERY) with its fully dedicated Business Unit (EUROSCREEN FAST) providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world.

EUROSCREEN has also developped a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2.

EUROSCREEN has discovery and licensing partnerships with Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon, GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex, Monogram Biosciences, Novartis and Pfizer.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

ALFRED GRAY
Visit website